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Case presentation
Herewith we report a 54-year-old woman with a history 
of ovarian cancer, diagnosed 11 years before and treated 
surgically followed by chemotherapy. She also suffered 
from hypertension treated with bisoprolol (5 mg/day) 
for the past five years. During oncological follow-up, 
nine years after surgery, on abdominal CT she was di-
agnosed with bilateral adrenal tumours. On admission 
her main complaint was headache and bilateral shank 
ache of six months’ duration.
She was eventually diagnosed with non-functional 
bilateral adrenal tumours, being benign lipid-rich adeno-
mas (21 mm and density of 7 Hounsfield Units [HU], and 
10 mm and density of 3 HU). In addition, she presented 
with slightly increased parathormone level with nor-
mocalcaemia. No detectable parathyroid adenoma was 
seen on ultrasound examination or on MIBI scintiscan. 
Increased alkaline phosphatase and suboptimal concen-
tration of vitamin D were detected (Tab. I). Therefore, 
primary hyperparathyroidism was excluded. Renal and 
thyroid function was normal. Her recent oncological 
assessment (three months earlier) showed complete 
remission of ovarian cancer. Thus, diagnosis of bone 
metastases was unlikely. On densitometry T-score in the 
lumbar spine and in the femoral neck were (–)1.3 and 
(–)0.6, respectively. A bone scintiscan indicated increased 
tracer uptake in both parietal and zygomatic bones, 
jaws, and mandible as well as in the shafts of both tibia 
bones, suggesting focally increased bone metabolism 
(Fig. 1A). Her scull on X-ray examination presented dif-
fused poorly demarcated sclerotic changes with slight 
thickening of the frontal bone. On X-ray of both tibiae 
no visible changes were detected. She was eventually 
diagnosed with Paget’s disease and treated with orally 
administrated alendronate (40 mg/week) with calcium 
supplementation (1000 mg/day) and cholecalciferol 
(4000 IU/day) for six months. The therapy resulted in 
a significant improvement of symptoms; the bone pain 
in the scull and tibiae subsided. Blood tests following 
six-month therapy (Tab. I) revealed normalisation of 
parathormone level (50 pg/mL) accompanied by increase 
in 25-hydroxyvitamin D concentration and decrease in 
alkaline phosphatase, while serum osteocalcin (mea-
sured for the first time) was normal. A repeated bone 
scintiscan was performed, demonstrating no foci of 
pathologically increased uptake in the skeleton (Fig. 1B).
Discussion
Paget’s disease (PD) is a focal disorder of bone remodel-
ling that progresses slowly and leads to changes in the 
shape and size of affected bones. It is the second most 
common metabolic bone disease following osteoporosis 
in some parts of the world. It affects 2–4% of adults 
over 55 years of age. The disease can be quite easily 
diagnosed and effectively treated, but its pathogenesis 
remains incompletely understood [1].
There is a slight male preponderance in PD inci-
dence. Affected bone becomes enlarged and mechani-
cally weakened, leading to pain, skeletal deformities, 
and fractures. However, most PD patients are asymp-
tomatic and diagnosed because of increased alkaline 
phosphatase activity or incidental X-ray findings. Most 
commonly the disease involves the axial skeleton, 
particularly the pelvis, lumbosacral spine, skull, or less 
frequently — femur or tibia. The disease may be limited 
to one or a few bones or widespread [2].
Clinically PD may present with constant, diffuse or 
localised pain. Deformities such as bowing of long bones 
occur due to abnormal distribution of forces. Mechani-
cal pain of the affected limb can arise due to cortical fis-
suring. The most common neurological complication is 
deafness arising from compression of the eighth cranial 
nerve. Other neurological problems include vertigo, 
spinal cord compression, local compressive syndromes, 
Ewa Cyranska-Chyrek, MD, PhD, Department of Endocrinology, Metabolism, and Internal Medicine,  
Poznan University of Medical Sciences, Poland, 49 Przybyszewskiego St, 60–355 Poznan, tel: (+48) 61 869 13 30, fax: (+48) 61 869 16 82; 
e-mail: ewacyranska@gmail.com

454
Reason for shank ache Ewa Cyranska-Chyrek et al.
C
l
in
iC
a
l
 v
ig
n
e
t
t
e
a week might be an effective and well-tolerated option 
for patients with PD with less severe changes.
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other cranial nerve palsies, hydrocephalus, and brain 
stem compression from basilar invagination [3].
The diagnosis of PD can be made on the basis of 
increased markers of bone remodelling, accompanied 
by focally increased tracer uptake on bone scintiscan. 
The first and only sign of PD is often elevated ALP level. 
Isotope bone scanning is the best method of detecting the 
extent of skeletal involvement [4]. Pagetic lesions may be 
more easily detected by bone scintigraphy than conven-
tional radiology, due to its higher sensitivity. Paget disease 
diagnosis is made by exclusion, taking into consideration 
vitamin D deficiency, hyperparathyroidism, hyperthy-
roidism, renal osteodystrophy, malignancy, fibrous dys-
plasia, chronic osteomyelitis, and bone metastases [3, 5].
Bisphosphonate therapy is indicated for patients 
with symptomatic disease and should also be consid-
ered in patients in whom localisation of affected bones 
implies the risk of complications. The treatment of 
choice is a single infusion of zoledronic acid; however, 
literature data and our case demonstrate that courses 
of oral alendronate or risedronate are also effective [1]. 
Besides osteoporosis, alendronate is also FDA-approved 
for the treatment of PD. Our report demonstrates that 
oral therapy with alendronate administered once 
table i. Biochemical parameters characterising calcium-phosphate balance and bone metabolism on diagnosis and following 
alendronate therapy
Parameter Reference range Value on diagnosis Interpretation Value after therapy Interpretation
Ionised calcium [mg/dL] 4.2–5.2 5.27 ≠ 5.49 ≠
Total calcium [mg/dL] 8.80–10.20 10.11 ´ 9.95 ´
Phosphate [mg/dL] 2.7–4.5 4.08 ´ 3.34 ´
Parathormone [pg/mL] 15–65 73 ≠ 50 ´
25-OH vitamin D [ng/mL] 30–80 25 Ø 60 ´
Alkaline phosphatase [U/L] 35–105 156 ≠ 128 ≠
Serum osteocalcin [ug/L] 5–25 – – 21 ´
Calcinuria [mg/24h] 100–320 224 ´ 233 ´
Figure 1. Whole-body bone scintiscan of a patient on diagnosis demonstrating an increased uptake in both parietal and zygomatic bones, 
jaws, and mandible as well as in the shafts of both tibia bones (a), and six months after oral therapy with alendronate (B)
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